IL148936A0 - Modulation of t cell differentiation for the treatment of t helper cell mediated diseases - Google Patents
Modulation of t cell differentiation for the treatment of t helper cell mediated diseasesInfo
- Publication number
- IL148936A0 IL148936A0 IL14893600A IL14893600A IL148936A0 IL 148936 A0 IL148936 A0 IL 148936A0 IL 14893600 A IL14893600 A IL 14893600A IL 14893600 A IL14893600 A IL 14893600A IL 148936 A0 IL148936 A0 IL 148936A0
- Authority
- IL
- Israel
- Prior art keywords
- modulation
- treatment
- mediated diseases
- cell
- helper
- Prior art date
Links
- 230000024245 cell differentiation Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 210000002443 helper t lymphocyte Anatomy 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Transplantation (AREA)
- Otolaryngology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16054299P | 1999-10-20 | 1999-10-20 | |
PCT/US2000/028827 WO2001029070A2 (en) | 1999-10-20 | 2000-10-18 | Modulation of t cell differentiation for the treatment of t helper cell mediated diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
IL148936A0 true IL148936A0 (en) | 2002-09-12 |
Family
ID=22577314
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL14893600A IL148936A0 (en) | 1999-10-20 | 2000-10-18 | Modulation of t cell differentiation for the treatment of t helper cell mediated diseases |
IL148936A IL148936A (en) | 1999-10-20 | 2002-03-27 | Use of an agonist and t-cell cytokine receptor antibody in the preparation of a medicament for treating an allergic disorder |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL148936A IL148936A (en) | 1999-10-20 | 2002-03-27 | Use of an agonist and t-cell cytokine receptor antibody in the preparation of a medicament for treating an allergic disorder |
Country Status (13)
Country | Link |
---|---|
US (3) | US20040234522A1 (ko) |
EP (1) | EP1222209A2 (ko) |
JP (1) | JP4931310B2 (ko) |
KR (3) | KR20080068767A (ko) |
CN (1) | CN1279054C (ko) |
AU (2) | AU1095001A (ko) |
BR (1) | BR0015055A (ko) |
CA (1) | CA2389317A1 (ko) |
IL (2) | IL148936A0 (ko) |
MX (1) | MXPA02003897A (ko) |
NZ (1) | NZ531141A (ko) |
WO (1) | WO2001029070A2 (ko) |
ZA (1) | ZA200202468B (ko) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ531141A (en) * | 1999-10-20 | 2005-07-29 | Genentech Inc | Modulation of T cell differentiation for the treatment of T helper cell mediated diseases |
US7393532B1 (en) | 2000-10-18 | 2008-07-01 | Genentech, Inc. | Modulation of T cell differentiation for the treatment of T helper cell mediated diseases |
AU2003280410B8 (en) * | 2002-01-18 | 2009-04-23 | Zymogenetics, Inc. | Cytokine receptor zcytor17 multimers |
US9738700B2 (en) | 2002-01-18 | 2017-08-22 | Zymogenetics Inc. | ZCYTOR17 heterodimeric cytokine receptor |
WO2004069173A2 (en) | 2003-01-31 | 2004-08-19 | The Trustees Of The University Of Pennsylvania | Methods for modulating an inflammatory response |
CN1921886A (zh) * | 2004-02-17 | 2007-02-28 | 先灵公司 | 调节细胞因子活性的方法;相关药剂 |
EP1828250A2 (en) * | 2004-12-16 | 2007-09-05 | Genentech, Inc. | Methods for treating autoimmune disorders |
EP2046809B1 (en) * | 2006-07-19 | 2016-12-07 | The Trustees Of The University Of Pennsylvania | Wsx-1/il-27 as a target for anti-inflammatory responses |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4275149A (en) * | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
ZA811368B (en) | 1980-03-24 | 1982-04-28 | Genentech Inc | Bacterial polypedtide expression employing tryptophan promoter-operator |
NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5010182A (en) | 1987-07-28 | 1991-04-23 | Chiron Corporation | DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides |
IL87737A (en) | 1987-09-11 | 1993-08-18 | Genentech Inc | Method for culturing polypeptide factor dependent vertebrate recombinant cells |
AU4005289A (en) | 1988-08-25 | 1990-03-01 | Smithkline Beecham Corporation | Recombinant saccharomyces |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5009772A (en) | 1989-02-27 | 1991-04-23 | Kerr-Mcgee Corporation | Solvent extraction process |
JPH04503957A (ja) | 1989-03-07 | 1992-07-16 | ジェネンテク,インコーポレイテッド | 脂質とオリゴヌクレオチドの共有結合コンジュゲート |
FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
EP0471796A4 (en) | 1989-05-10 | 1993-05-05 | Sloan Kettering Institute For Cancer Research | Stably transformed eucaryotic cells comprising a foreign transcribable dna under the control of a pol iii promoter |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
WO1991004753A1 (en) | 1989-10-02 | 1991-04-18 | Cetus Corporation | Conjugates of antisense oligonucleotides and therapeutic uses thereof |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
CA2405246A1 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with alterred binding properties |
US5206161A (en) | 1991-02-01 | 1993-04-27 | Genentech, Inc. | Human plasma carboxypeptidase B |
IE922437A1 (en) * | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
US5756096A (en) * | 1991-07-25 | 1998-05-26 | Idec Pharmaceuticals Corporation | Recombinant antibodies for human therapy |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
DK1136556T3 (da) | 1991-11-25 | 2005-10-03 | Enzon Inc | Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner |
ATE199392T1 (de) * | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
WO1997033551A2 (en) | 1996-03-15 | 1997-09-18 | Millennium Pharmaceuticals | Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation |
AU2937597A (en) * | 1996-05-10 | 1997-12-05 | Biogen, Inc. | Common gamma chain blocking agents |
US5792850A (en) * | 1996-05-23 | 1998-08-11 | Zymogenetics, Inc. | Hematopoietic cytokine receptor |
NZ531141A (en) * | 1999-10-20 | 2005-07-29 | Genentech Inc | Modulation of T cell differentiation for the treatment of T helper cell mediated diseases |
EP1505148B1 (en) * | 2002-04-26 | 2009-04-15 | Chugai Seiyaku Kabushiki Kaisha | Methods of screening for agonistic antibodies |
ATE506987T1 (de) * | 2002-12-31 | 2011-05-15 | Schering Corp | Il-27 et il-2 pour le traitement du cancer |
EP1828250A2 (en) * | 2004-12-16 | 2007-09-05 | Genentech, Inc. | Methods for treating autoimmune disorders |
-
2000
- 2000-10-18 NZ NZ531141A patent/NZ531141A/en not_active IP Right Cessation
- 2000-10-18 AU AU10950/01A patent/AU1095001A/en not_active Abandoned
- 2000-10-18 MX MXPA02003897A patent/MXPA02003897A/es active IP Right Grant
- 2000-10-18 WO PCT/US2000/028827 patent/WO2001029070A2/en active Application Filing
- 2000-10-18 BR BR0015055-0A patent/BR0015055A/pt not_active Application Discontinuation
- 2000-10-18 CA CA002389317A patent/CA2389317A1/en not_active Abandoned
- 2000-10-18 EP EP00972264A patent/EP1222209A2/en not_active Withdrawn
- 2000-10-18 CN CNB008171769A patent/CN1279054C/zh not_active Expired - Fee Related
- 2000-10-18 IL IL14893600A patent/IL148936A0/xx unknown
- 2000-10-18 KR KR1020087017088A patent/KR20080068767A/ko not_active Application Discontinuation
- 2000-10-18 KR KR1020027005032A patent/KR100840033B1/ko not_active IP Right Cessation
- 2000-10-18 KR KR1020077028670A patent/KR100874280B1/ko not_active IP Right Cessation
- 2000-10-18 JP JP2001531868A patent/JP4931310B2/ja not_active Expired - Fee Related
-
2002
- 2002-03-27 IL IL148936A patent/IL148936A/en not_active IP Right Cessation
- 2002-03-27 ZA ZA200202468A patent/ZA200202468B/xx unknown
-
2003
- 2003-09-15 US US10/663,158 patent/US20040234522A1/en not_active Abandoned
-
2006
- 2006-01-27 AU AU2006200374A patent/AU2006200374B2/en not_active Ceased
- 2006-09-29 US US11/537,572 patent/US20070134238A1/en not_active Abandoned
-
2009
- 2009-05-07 US US12/437,452 patent/US20110097325A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2001029070A8 (en) | 2001-09-20 |
EP1222209A2 (en) | 2002-07-17 |
AU2006200374B2 (en) | 2009-12-10 |
US20070134238A1 (en) | 2007-06-14 |
US20110097325A1 (en) | 2011-04-28 |
ZA200202468B (en) | 2003-06-25 |
KR20070121855A (ko) | 2007-12-27 |
PL355284A1 (en) | 2004-04-05 |
WO2001029070A3 (en) | 2002-05-02 |
AU1095001A (en) | 2001-04-30 |
KR100840033B1 (ko) | 2008-06-19 |
WO2001029070A2 (en) | 2001-04-26 |
CN1279054C (zh) | 2006-10-11 |
CN1409726A (zh) | 2003-04-09 |
MXPA02003897A (es) | 2002-12-13 |
US20040234522A1 (en) | 2004-11-25 |
CA2389317A1 (en) | 2001-04-26 |
KR20080068767A (ko) | 2008-07-23 |
AU2006200374A1 (en) | 2006-02-23 |
JP4931310B2 (ja) | 2012-05-16 |
JP2003512824A (ja) | 2003-04-08 |
BR0015055A (pt) | 2002-07-16 |
IL148936A (en) | 2010-12-30 |
KR100874280B1 (ko) | 2008-12-18 |
KR20020048971A (ko) | 2002-06-24 |
NZ531141A (en) | 2005-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU3673499A (en) | Hydrogel for the therapeutic treatment of aneurysms | |
AUPQ302899A0 (en) | Implants for the use in the treatment of aneurysmal disease | |
IL144378A0 (en) | Platform for the differentiation of cells | |
AU2072201A (en) | Agents and methods for the treatment of proliferative diseases | |
AU6910600A (en) | Methods for the treatment of mental disorders | |
AU3009801A (en) | Combinations of medicaments for treating viral diseases | |
AU7622000A (en) | Compounds for the treatment of viral-mediated diseases | |
HUP0200738A3 (en) | Method of the treatment of incontinence | |
HUP0104963A3 (en) | Compositions for the treatment of skin diseases | |
IL148936A0 (en) | Modulation of t cell differentiation for the treatment of t helper cell mediated diseases | |
AU1878201A (en) | Composition for the treatment of damaged tissue | |
NZ513686A (en) | Treatment of trauma | |
IL133760A0 (en) | Composition for the treatment of dandruff | |
HK1038510B (zh) | 使用神經營養因子興奮劑治療眼神經變性疾病 | |
AU3004000A (en) | Methods for the treatment of apolipoprotein e related diseases | |
PL347976A1 (en) | Isonipecotamides for the treatment of integrin−mediated disorders | |
HUP0100365A3 (en) | Combination therapy for the treatment of aids | |
AU2566201A (en) | Compounds and methods for the treatment of pain | |
AU1405001A (en) | Treatment of diseases | |
AU2184202A (en) | Imidazolone derivatives for the treatment of viral diseases | |
HK1043938A1 (en) | Composition for the treatment of psoriasis | |
GB2363604B (en) | S-nitrosothiols as agents for the treatment of circulatory dsyfunctions | |
AU6016499A (en) | Medical treatment trolley | |
GB9904252D0 (en) | Composition for the treatment of pain | |
GB2341099B (en) | Clinical table for treatment of the spine |